Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

UHMK1 (U2AF homology motif kinase 1)

Written2017-11Vanessa Cristina Arfelli, Leticia Fröhlich Archangelo
Department of Cellular and Molecular Biology and Pathogenic Bioagents, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.

Abstract UHMK1 (also known as KIS) is a serine/threonine kinase initially identified as a Stathmin interacting protein. UHMK1 is characterized by an N-terminal kinase domain and a C-terminal UHM motif. Through the UHM motif, the protein is capable of interacting with splicing factors, such as SF1 and SF3B1, involved in early steps of spliceosome assembly. UHMK1 is ubiquitously but preferentially expressed in the developing nervous system, where it plays a role in mRNA processing, translational enhancing, neurite outgrowth and postsynaptic plasticity. Protein interactions between UHMK1 and a range of proteins pointed to its function in different cellular processes, such as RNA metabolism, cell cycle progression, cell migration and membrane trafficking. More recently, a role of UHMK1 in cell differentiation has also been proposed.

Keywords phosphorylation; splicing; cell-cycle control; nervous system

(Note : for Links provided by Atlas : click)


HGNC Alias symbKIS
HGNC Previous nameU2AF homology motif (UHM) kinase 1
LocusID (NCBI) 127933
Atlas_Id 41071
Location 1q23.3  [Link to chromosome band 1q23]
Location_base_pair Starts at 162497818 and ends at 162529631 bp from pter ( according to GRCh38/hg38-Dec_2013)  [Mapping UHMK1.png]
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)


  Figure 1. Genomic organization, alternative splicing and protein isoforms of UHMK1. Exons are represented by numbered blue boxes and introns by the black line. The positions of the exons within the genome (NC_000001.11) are numbered. Exon joining is represented for each transcript by light green, purple and orange continuous lines; dashed lines indicate the respective protein isoform; dotted lines indicate the alternatively first exon usage. Size of the transcript variants are shown in parentheses. The transcript variant 1 codes for the longer protein (UHMK1 isoform 1, light green). The transcript variant 2 comprises an alternative first exon (light purple box), which encodes the distinct 15 amino acids N-terminal of the protein (UHMK1 isoform 2, purple). The transcript variant 3 lacks exon 7, whose excision results in a frameshift and early stop codon in exon 8. The resulting UHMK1 isoform 3 (orange), exhibits a distinct C-terminal formed by 3 aminoacids encoded by the beginning of exon 8. Sizes were scaled up, where 0.5 cm symbolizes 150 bp of exonic region (blue boxes) and 624 bp of intronic regions (black line). Number and position of aminoacids are depicted for each isoform.
Description The UHMK1 gene is located on the chromosome 1, band q23, orientated in the plus (+) strand. The genomic locus spans 32456 base pairs (NC_000001.11), contains 8 exons and two alternative first exons.
Transcription Three alternatively spliced transcripts of 8535, 8194 and 8446 base pairs are formed (NM_175866, NM_001184763 and NM_144624, respectively). The transcript variant 1 (NM_175866) codes for the longest protein isoform, which has 419 amino acids in length (isoform 1; NP_787062). The transcript variant 2 (NM_001184763) differs in the 5' UTR and initiates translation at the alternative start codon. The resulting protein (isoform 2; NP_0011716921) of 345 amino acids has a distinct 15 amino acids N-terminal, encoded by the alternative exon 1, and the remaining 330 amino acids encoded by exons 2-8. The transcript variant 3 (NM_144624) lacks exon 7, which results in a frame shift and early stop codon within exon 8. The encoded protein (isoform 3; NP_653225) of 344 residues, shares the first 341 amino acids (exons 1-6) with isoform 1, differing only in the last 3 amino acids at the C-terminal (Figure 1). An additional processed transcript of 3345 bp (ENST00000282169.8) retaining intron 2 (between exons 2 and 3), which does not contain an open reading frame (ORF) has been annotated for this gene. Moreover, the first 540 nucleotides of UHMK1 locus (NC_000001.11) are shared with the LOC105371497 gene, which produces a 708 bp long non-coding RNA (XR_922225.1), transcribed in the opposite direction of UHMK1 (


  Figure 2. Diagram representing UHMK1 protein and the posttranslational modifications. UHMK1 is characterized by an N-terminal kinase core of 282 aminoacids, represented in green and a C-terminal UHM of 100 aminoacids, represented in violet. All residues described to be phosphorylated or ubiquitinated in large scale proteomic studies are depicted. Source: Phosphoproteomic databases PhosphoSitePlus ( UHM: U2AF homology motif (modified from Archangelo, et al. 2013).
Description UHMK1 is a serine/threonine kinase with calculated molecular weight of 46.5 kDa and a theoretical pI of 5.59 (PhosphoSite Plus). The primary sequence of the protein is characterized by an N-terminal kinase core (282 aminoacids) and the C-terminal U2AF homology motif (UHM), responsible for establishing protein interactions with UHM-ligand motifs (ULM), particularly present among splicing factors (Kielkopf et al., 2004; Manceau et al., 2006). UHMK1 phosphorylates preferentially proline directed serine residues on its target proteins (Maucuer et al., 2000). The lysine 54 within the N-terminal region is essential for its kinase activity and autophosphorylation activity has been observed (Boehm et al., 2002; Maucuer et al., 1997). A variety of large scale proteomic studies identified two types of posttranslational modifications within UHMK1, namely lysine-ubiquitination (K190-ub, K282-ub, K383-ub and K387-ub) and phosphorylation (Y197-p, S283-p and S290-p) as indicated at the phosphoproteomic database PhosphoSitePlus ( (Figure 2).
Expression UHMK1 is ubiquitously expressed throughout rat and human tissues, with enriched expression in the nervous system (Bieche et al., 2003; Caldwell et al., 1999; Maucuer et al., 1997). Uhmk1 mRNA is expressed during rat embryonic development and increases after birth and during the first month of brain development (Bieche et al., 2003). In the adult brain, in situ hybridization revealed remarkable expression in the substantia nigra and some sensorial and motor nuclei in the brain stem (Bieche et al., 2003). In the human brain, UHMK1 expression was detected in all regions examined, with highest levels in the deeper cortical layers. Strong expression was observed in dentate gyrus, CA1, CA3 and CA4 regions of the hippocampus, in Purkinje cells and granule cell layer of the cerebellum. No expression was detected in the white matter (Bristow et al., 2009).
In the hematopoietic compartment, high levels of UHMK1 transcripts were observed in differentiated lymphocytes (CD4+, CD8+ and CD19+) compared to the progenitor enriched subpopulation (CD34+) or leukemia cell lines. UHMK1 expression was upregulated in megakaryocytic-, monocytic- and granulocytic-induced differentiation of leukemia cell lines and in erythrocytic-induced differentiation of primary CD34+ cells (Barbutti et al., 2017).
Levels of UHMK1 protein are induced by mitogens. In serum starved cells, UHMK1 expression was reduced in contrast to serum stimulated cells (Boehm et al., 2002; Crook et al., 2008; Petrovic et al., 2008). UHMK1 expression increased after quiescent peripheral blood lymphocytes (PBLs) were induced to proliferate upon mitogen activation (Barbutti et al., 2017). Moreover, the amount of UHMK1 protein varies throughout the cell cycle. In synchronized cells, UHMK1 accumulates in G1 phase and decreases during S phase of the cell cycle (Archangelo et al., 2013).
Little is known about the transcriptional regulation of UHMK1, which was described as direct target of the transcription factors GABP (Crook et al., 2008) and FOXM1 (Petrovic et al., 2008). The core promoter region of UHMK1 was described within -141 to -41 base pairs upstream of the transcription start site and has no consensus sequences for TATA or CCAAT boxes. Instead, it has GC-box and 3 Ets-binding sites (EBS-1, EBS-2 and EBS-3), which are essential for the promoter activity, in vitro. The regions spanning EBS-1 and EBS-2 (-103/-73 bp), and EBS-3 (-52/-42 bp) bind GABP in response to serum, leading to UHMK1 expression, cell migration and cell cycle progression of VSCM cells (Crook et al., 2008).
FoxM1 binds an internal regulatory region within UHMK1 and transactivates its expression in vitro. FoxM1 appears to be essential for serum-dependent activation of UHMK1 mRNA expression, as assessed in FoxM1-/- MEF cells. It was suggested that FoxM1-induced UHMK1 expression is required for UHMK1-mediated phosphorylation and consequently degradation of CDKN1B (p27Kip1) (Petrovic et al., 2008).
Furthermore, UHMK1 was described as transcriptional target of the WD repeat domain 5 (WDR5), a core component of the KMT2A (MLL) / SETD1A complex, known for its methyltransferase activity on H3 lysine 4 (H3K4). The H3K4me3 epigenetic modification correlates with gene activation, thus it is suggested that WDR5-mediated H3K4me3 at UHMK1 locus promotes its expression (Chen et al., 2015).
  Figure 3. Subcellular localization of Uhmk1. Confocal image of HeLa cells transiently transfected with plasmid expressing ha-tagged Uhmk1 (pECE-HA-Kis; Manceau et al, 2008). Ectopic Uhmk1 localizes mainly to the nucleus and to a lesser extent to the cytoplasm. The anti-Kis 3B12 antibody (Manceau et al, 2012) and Phalloidin (Invitrogen A1238) were used to detected Uhmk1 and Actin, respectively. 63x objective, zoom 2,5 x. Personal data.
Localisation The UHMK1 protein localizes mainly to the nucleus and to a lesser extent to the cytoplasm (Boehm et al., 2002; Maucuer et al., 1997) (Figure 3). Shuttling between nucleus and cytoplasm has been described for the GFP-fused protein by fluorescence recovery after photobleaching (FRAP) (Francone et al., 2010). The kinase domain is essential for the protein nuclear localization, since deletion mutants of this domain, particularly the residues 1-211, extinguished Uhmk1 signal in immunofluorescence analysis (Manceau et al., 2008). Overexpressed ha-tagged Uhmk1 localized to the RNA granules of axon and dendrites of cortical neurons (Cambray et al., 2009). Also, a nucleolar enriched localization was observed when ha-tagged Uhmk1 was co-expressed with its GFP-fused interacting partner PIMREG (Archangelo et al., 2013).
  Figure 4. Potential functions of UHMK1. 1- UHMK1 interacts with and phosphorylates the splicing factors SF1 and SF3B1. 2- UHMK1 counteracts the inhibitory effect of p27Kip1 on cell cycle. Upon mitogenic activation, UHMK1 is upregulated and phosphorylates p27Kip1, which is exported from the nucleus and targeted for degradation by the proteasome. 3- UHMK1 impairs cell migration through negatively regulating the microtubule destabilizing protein Stathmin (STMN). UHMK1-mediated phosphorylation of STMN on S38 targets the protein for degradation. 4- UHMK1 regulates the secretory pathway in neurons and endocrine cells through its interaction with the peptidylglycine α-amidating mono-oxigenase (PAM). 5- UHMK1 interacts with components of neuronal RNA granules, such as KIF3A, NonO and eEF1A. It also associates with RNP-transported mRNAs and stimulates translation driven by the β-actin 3' UTR. 6- UHMK1 interacts with and phosphorylates the proliferation marker PIMREG, suggesting a potential role in regulating proliferation. Black arrow: represents the mitogen-dependent activation of UHMK1. Grey arrows: indicate the UHMK1-mediated phosphorylation of target proteins. Grey dotted arrows: represent the fate of the UHMK1 phosphorylated proteins targeted for degradation. P: phosphorylation; Ub: ubiquitination. Illustration was drawn using Servier Medical Art.
Function UHMK1 was described to interact with a range of proteins, shedding light on different functions of this protein in diverse cellular processes (Figure 4).
UHMK1 is the only kinase that possesses the N-terminal kinase core juxtaposed to a C-terminal U2AF homology motif (UHM) (Maucuer et al., 1997). Through the UHM motif, UHMK1 interacts with the splicing factors SF1 and SF3B1 (Manceau et al., 2008). Upon interaction, UHMK1 phosphorylates SF1, which enhances SF1 specific binding to U2AF65 and reduces the SF1-U2AF65 binding to the 3' splice site RNA (Chatrikhi et al., 2016; Manceau et al., 2006). In addition, UHMK1 expression is necessary for normal phosphorylation of SF1 in vivo (Manceau et al., 2012). The fact that UHMK1 interacts with and regulates splicing factors suggests that UHMK1 might be involved in RNA metabolism.
Since UHMK1 is highly expressed in neurons, it is expected to exerts important functions in the nervous system. It was demonstrated an abnormal phosphorylation of SF1 in brain extracts of neonate Uhmk1-/- mice. Also, Uhmk1 deletion resulted in increased ratio of pre-mRNA relative to mRNA, and consequently down-regulation of brain specific genes, like cys-loop ligand-gated ion channels and metabolic enzymes. Although adult Uhmk1-/- mice did not present an obvious phenotype, animal behavior was affected. The Uhmk1-/- mice displayed locomotor hyperactivity, reduced fear conditioning and learning capacities from aversive stimuli (Manceau et al., 2012).
The murine Uhmk1 was described to interact with known components of neuronal RNA granules, such as KIF3A, NONO and EEF1A1. The protein colocalizes with KIF3A kinesin in neurites and is required for neuritic outgrowth in cortical mouse neurons. Furthermore, Uhmk1 associates with RNP-transported mRNAs and stimulate translation driven by the β-actin 3' UTR, suggesting that Uhmk1 contributes to modulate translation in RNA-transporting granules as a result of local signals (Cambray et al., 2009). Still, comparison of primary cultures derived from Uhmk1-/- mice did not reveal a significant difference in neuritic arborization of cortical neurons (Manceau et al., 2012).
Furthermore, a study investigating Uhmk1 action on hippocampal synaptic plasticity in mice, showed that Uhmk1 knockdown impaired spine development, altered actin dynamics, and reduced postsynaptic responsiveness. Moreover, Uhmk1 depletion resulted in decrease of the postsynaptic scaffolding protein PSD-95 and of AMPA receptor subunits. Thus Uhmk1 enhances translation of AMPA receptors and stimulates dendritic spine remodeling (Pedraza et al., 2014).
Another described function of UHMK1 involves the regulation of secretory pathway in neurons and endocrine cells through its interaction with peptidylglycine α-amidating mono-oxigenase (PAM) (Alam et al., 1996). PAM cytosolic domain (CD) phosphorylation by UHMK1 (Ser-949) is required for the correct routing of this protein and consequently for its ability to affect trafficking in the regulated secretion pathway (Alam et al., 2001; Caldwell et al., 1999). Lately, it was described an intramembrane proteolysis pathway for PAM, generating a soluble fragment of the cytosolic domain (sf-CD), which accumulates in the nucleus in a phosphorylation-dependent manner, modulating the expression of genes involved in the secretory pathway. UHMK1 phosphorylates sf-CD, diminishing its localization in the nucleus and negatively regulating the expression of a subset of genes (Francone et al., 2010; Rajagopal et al., 2010).
An extensively documented function of UHMK1 is its ability to positively regulate cell cycle progression through phosphorylation and inhibition of the cyclin dependent kinase inhibitor (CDKI) p27Kip1. Upon mitogenic activation, UHMK1 expression is upregulated and phosphorylates p27Kip1 on serine 10 (Ser10). As a consequence, p27Kip1 is exported from nucleus to cytoplasm, where it is targeted to the proteasome and degraded, and has no longer inhibitory effect on cell cycle. Thus, UHMK1 promotes cell cycle re-entry by inactivating p27Kip1 following growth factor stimulation (Boehm et al., 2002).
Another important target of UHMK1 is the microtubule-destabilizing protein, Stathmin (Maucuer et al., 1995). UHMK1 interacts with and phosphorylates Stathmin on serine 38 (Ser38), targeting this protein to proteasome. Through negative regulation of Stathmin, UHMK1 alter microtubule dynamics and consequently impairs cell migration (Langenickel et al., 2008).
UHMK1 expression is upregulated upon hematopoietic cell differentiation, thus a possible role of UHMK1 in cell differentiation was proposed (Barbutti et al., 2017). This idea was supported by the fact that UHMK1 mRNA is highly expressed in the mature brain and in terminally differentiated neural cells (Bieche et al., 2003) as well as during osteoclasts differentiation (Choi et al., 2016). The human UHMK1 shares high homology with a number of species as depicted in Table 1. PIMREG (previously known as FAM64A; CATS) is a proliferation marker shown to interact with UHMK1. The fact that UHMK1 interacts with and phosphorylates PIMREG suggests that UHMK1 regulates PIMREG function and/or localization. Nevertheless, the functional implication of this interaction remains elusive (Archangelo et al., 2013).
Homology The human UHMK1 shares high homology with a number of species as depicted in Table 1. The human UHMK1 shares high homology with a number of species as depicted in Table 1.
Table 1. Homology between the human UHMK1 and other species
Homo sapiens UHMK1SymbolProtein (% Identity)DNA(% Identity)
vs. P. troglodytes
vs. M. mulatta
99.8 (XP_001174268)
99.8 (NP_001253697)
99.7 (XM_001174268)
99.0 (NM_001266768)
vs. C. lupusUHMK199.8 (XP_536143) 95.8 (XM_536143)
vs. B. taurusUHMK199.8 (NP_001192514) 95.9 (NM_001205585)
vs. M. musculusUhmk199.3 (NP_034763) 93.0 (NM_010633)
vs. R. norvegicusUhmk199.3 (NP_058989)92.6 (NM_017293)
vs. G. gallusUHMK188.2 (XP_015145890) 81.6 (XM_015290404)
vs. D. reriouhmk173.6 (NP_001070127) 69.4 (NM_001076659)



Somatic Recurrent mutations have not been identified for the UHMK1 gene. Nonetheless, more than 160 unique mutations were reported in this gene in the catalogue of somatic mutations in cancer database (COSMIC), mainly in lung, gastric, esophageal, colon, rectal and hepatocellular/liver cancer (

Implicated in

Entity Breast cancer
Note Erlotinib resistence in breast cancer treatment was attributed to p27Kip1 cytoplasmic localization. UHMK1 depletion by siRNA enhanced erlotinib cytotoxicity in EGFR-expressing breast cancer cells, due to its accumulation in the nucleus and reduced p27Kip1 cytoplasmic localization (Zhang et al., 2010). Besides, UHMK1 expression was reported to be inhibited in a dose-dependent manner by the anti-HER2 antibody trastuzumab, used for treatment of human metastatic breast cancer with HER2 overexpression (Le et al., 2005).
Entity Neurological tumors
Note Higher levels of UHMK1 transcripts were observed in small cohort of neurological tumors associated with neurofibromatosis type 1 (NF1). Among the NF1-associated tumors analyzed, plexiform neurofibroma and malignant peripheral nerve sheath tumors (MPNSTs) presented higher UHMK1 mRNA levels compared to dermal neurofibroma (Bieche et al., 2003).
Entity Bladder cancer
Note Silencing of WDR5, a protein shown to be upregulated in bladder cancer, reduced the H3K4me3 epigenetic marker on its target genes, such as UHMK1 and consequently downregulated UHMK1 expression in bladder cancer cells (Chen et al., 2015).
Entity Hematological malignancies
Note No aberrant expression was observed in patient samples with myelodysplastic syndrome (MDS), acute myeloid (AML) or lymphoblastic (ALL) leukemia. Nonetheless, in MDS patients, increased levels of UHMK1 expression positively impacted event free and overall survival (Barbutti et al., 2017).
Entity Schizophrenia
Note Puri and colleagues performed a fine mapping by genetic association and identified two SNPs within the UHMK1 gene (rs10494370, p =.004, and rs7513662, p = .043), which showed significant association with schizophrenia (Puri et al., 2007). The genetic association of these markers was confirmed in a second case-control (Puri et al., 2008). Nevertheless, the association of UHMK1 with schizophrenia is controversial since the data from different cohorts did not support the findings (Betcheva et al., 2009; Dumaine et al., 2011).
Entity Osteoporosis
Note The SNP rs16863247 was identified within the UHMK1 locus in a genome-wide association study (GWAS) carried out to identify genetic variants that influence bone mineral density (BMD) in east Asians. Thus, UHMK1 was described as a bone mineral density susceptibility gene for this ethnical group. The authors also showed opposed expression levels of UHMK1 during osteoblast and osteoclast differentiation and proposed that UHMK1 may play a role in bone metabolism by controlling osteoclast and osteoblast differentiation (Choi et al., 2016).
Entity Vascular remodeling and wound repair
Note Langenickel and coworkers demonstrated the importance of UHMK1 expression in controlling vascular remodeling and wound repair. These processes are characterized by vascular smooth muscle cell (VSCM) proliferation and cell migration, which can be achieved by inhibiting p27Kip1 and Stathmin, two known substrates of UHMK1. In a mouse model, deletion of Uhmk1 led to accelerated neointima formation and vessel occlusion, caused by increased migratory activity of VSMCs, as a consequence of diminished degradation of Stathmin (Langenickel et al., 2008).
Entity Corneal fibrosis
Note It was shown that FGF2-mediated proliferation of corneal endothelial cells (CECs) is partially dependent on UHMK1 upregulation and its inhibitory effects on CDK inhibitor p27Kip1 (Lee and Kay, 2011; Lee et al., 2011).
Entity Cerebral visual impairment
Note UHMK1 was recently reported among candidate genes for cerebral visual impairment (CVI), a major cause of low vision in childhood (Bosch et al., 2016).

To be noted

It is well accepted that UHMK1 promotes cell cycle re-entry by inactivating p27Kip1 following growth factor stimulation. Thus it is expected that abnormally elevated UHMK1 activity, which is supposed to relieve cells from p27Kip-dependent growth inhibition, could be involved in some aspects of tumor development. Nonetheless, no aberrant expression of UHMK1 has been reported amongst different cancer samples (Barbutti et al., 2017; Bieche et al., 2003), except in a few cases of neurological tumors associated with NF1 (Bieche et al., 2003). Hence, whether it plays a role in tumorigenesis or not remains largely elusive and must be further investigated.


Signaling mediated by the cytosolic domain of peptidylglycine alpha-amidating monooxygenase
Alam MR, Steveson TC, Johnson RC, Bäck N, Abraham B, Mains RE, Eipper BA
Mol Biol Cell 2001 Mar;12(3):629-44
PMID 11251076
The CATS (FAM64A) protein is a substrate of the Kinase Interacting Stathmin (KIS)
Archangelo LF, Greif PA, Maucuer A, Manceau V, Koneru N, Bigarella CL, Niemann F, dos Santos MT, Kobarg J, Bohlander SK, Saad ST
Biochim Biophys Acta 2013 May;1833(5):1269-79
PMID 23419774
The U2AF homology motif kinase 1 (UHMK1) is upregulated upon hematopoietic cell differentiation.
Barbutti I, Machado-Neto J, Arfelli V, Campos P, Traina F, Saad S, and Archangelo L.
2017. DOI: 10.1101/187385.
Case-control association study of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as the only susceptibility factor for schizophrenia in the Bulgarian population
Betcheva ET, Mushiroda T, Takahashi A, Kubo M, Karachanak SK, Zaharieva IT, Vazharova RV, Dimova II, Milanova VK, Tolev T, Kirov G, Owen MJ, O'Donovan MC, Kamatani N, Nakamura Y, Toncheva DI
J Hum Genet 2009 Feb;54(2):98-107
PMID 19158809
Quantitative RT-PCR reveals a ubiquitous but preferentially neural expression of the KIS gene in rat and human
Bièche I, Manceau V, Curmi PA, Laurendeau I, Lachkar S, Leroy K, Vidaud D, Sobel A, Maucuer A
Brain Res Mol Brain Res 2003 May 26;114(1):55-64
PMID 12782393
A growth factor-dependent nuclear kinase phosphorylates p27(Kip1) and regulates cell cycle progression
Boehm M, Yoshimoto T, Crook MF, Nallamshetty S, True A, Nabel GJ, Nabel EG
EMBO J 2002 Jul 1;21(13):3390-401
PMID 12093740
Novel genetic causes for cerebral visual impairment
Bosch DG, Boonstra FN, de Leeuw N, Pfundt R, Nillesen WM, de Ligt J, Gilissen C, Jhangiani S, Lupski JR, Cremers FP, de Vries BB
Eur J Hum Genet 2016 May;24(5):660-5
PMID 26350515
Expression of kinase interacting with stathmin (KIS, UHMK1) in human brain and lymphoblasts: Effects of schizophrenia and genotype
Bristow GC, Lane TA, Walker M, Chen L, Sei Y, Hyde TM, Kleinman JE, Harrison PJ, Eastwood SL
Brain Res 2009 Dec 8;1301:197-206
PMID 19747464
The novel kinase peptidylglycine alpha-amidating monooxygenase cytosolic interactor protein 2 interacts with the cytosolic routing determinants of the peptide processing enzyme peptidylglycine alpha-amidating monooxygenase
Caldwell BD, Darlington DN, Penzes P, Johnson RC, Eipper BA, Mains RE
J Biol Chem 1999 Dec 3;274(49):34646-56
PMID 10574929
Protein kinase KIS localizes to RNA granules and enhances local translation
Cambray S, Pedraza N, Rafel M, Garí E, Aldea M, Gallego C
Mol Cell Biol 2009 Feb;29(3):726-35
PMID 19015237
SF1 Phosphorylation Enhances Specific Binding to U2AF(65) and Reduces Binding to 3'-Splice-Site RNA
Chatrikhi R, Wang W, Gupta A, Loerch S, Maucuer A, Kielkopf CL
Biophys J 2016 Dec 20;111(12):2570-2586
PMID 28002734
Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation
Chen X, Xie W, Gu P, Cai Q, Wang B, Xie Y, Dong W, He W, Zhong G, Lin T, Huang J
Sci Rep 2015 Feb 6;5:8293
PMID 25656485
Genome-wide association study in East Asians suggests UHMK1 as a novel bone mineral density susceptibility gene
Choi HJ, Park H, Zhang L, Kim JH, Kim YA, Yang JY, Pei YF, Tian Q, Shen H, Hwang JY, Deng HW, Cho NH, Shin CS
Bone 2016 Oct;91:113-21
PMID 27424934
GA-binding protein regulates KIS gene expression, cell migration, and cell cycle progression
Crook MF, Olive M, Xue HH, Langenickel TH, Boehm M, Leonard WJ, Nabel EG
FASEB J 2008 Jan;22(1):225-35
PMID 17726090
Genetic and molecular exploration of UHMK1 in schizophrenic patients
Dumaine A, Maucuer A, Barbet A, Manceau V, Deshommes J, Méary A, Szöke A, Schürhoff F, Llorca PM, Lancon C, Leboyer M, Jamain S
Psychiatr Genet 2011 Dec;21(6):315-8
PMID 21399567
Signaling from the secretory granule to the nucleus: Uhmk1 and PAM
Francone VP, Ifrim MF, Rajagopal C, Leddy CJ, Wang Y, Carson JH, Mains RE, Eipper BA
Mol Endocrinol 2010 Aug;24(8):1543-58
PMID 20573687
U2AF homology motifs: protein recognition in the RRM world
Kielkopf CL, Lücke S, Green MR
Genes Dev 2004 Jul 1;18(13):1513-26
PMID 15231733
KIS protects against adverse vascular remodeling by opposing stathmin-mediated VSMC migration in mice
Langenickel TH, Olive M, Boehm M, San H, Crook MF, Nabel EG
J Clin Invest 2008 Dec;118(12):3848-59
PMID 19033656
HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways
Le XF, Pruefer F, Bast RC Jr
Cell Cycle 2005 Jan;4(1):87-95
PMID 15611642
PI 3-kinase/Rac1 and ERK1/2 regulate FGF-2-mediated cell proliferation through phosphorylation of p27 at Ser10 by KIS and at Thr187 by Cdc25A/Cdk2
Lee JG, Kay EP
Invest Ophthalmol Vis Sci 2011 Jan 21;52(1):417-26
PMID 20811053
Human corneal endothelial cells employ phosphorylation of p27(Kip1) at both Ser10 and Thr187 sites for FGF-2-mediated cell proliferation via PI 3-kinase
Lee JG, Song JS, Smith RE, Kay EP
Invest Ophthalmol Vis Sci 2011 Oct 17;52(11):8216-23
PMID 21948550
The protein kinase KIS impacts gene expression during development and fear conditioning in adult mice
Manceau V, Kremmer E, Nabel EG, Maucuer A
PLoS One 2012;7(8):e43946
PMID 22937132
Major phosphorylation of SF1 on adjacent Ser-Pro motifs enhances interaction with U2AF65
Manceau V, Swenson M, Le Caer JP, Sobel A, Kielkopf CL, Maucuer A
FEBS J 2006 Feb;273(3):577-87
PMID 16420481
Stathmin interaction with a putative kinase and coiled-coil-forming protein domains
Maucuer A, Camonis JH, Sobel A
Proc Natl Acad Sci U S A 1995 Apr 11;92(8):3100-4
PMID 7724523
Specific Ser-Pro phosphorylation by the RNA-recognition motif containing kinase KIS
Maucuer A, Le Caer JP, Manceau V, Sobel A
Eur J Biochem 2000 Jul;267(14):4456-64
PMID 10880969
KIS is a protein kinase with an RNA recognition motif
Maucuer A, Ozon S, Manceau V, Gavet O, Lawler S, Curmi P, Sobel A
J Biol Chem 1997 Sep 12;272(37):23151-6
PMID 9287318
KIS, a kinase associated with microtubule regulators, enhances translation of AMPA receptors and stimulates dendritic spine remodeling
Pedraza N, Ortiz R, Cornadó A, Llobet A, Aldea M, Gallego C
J Neurosci 2014 Oct 15;34(42):13988-97
PMID 25319695
FoxM1 regulates growth factor-induced expression of kinase-interacting stathmin (KIS) to promote cell cycle progression
Petrovic V, Costa RH, Lau LF, Raychaudhuri P, Tyner AL
J Biol Chem 2008 Jan 4;283(1):453-60
PMID 17984092
Confirmation of the genetic association between the U2AF homology motif (UHM) kinase 1 (UHMK1) gene and schizophrenia on chromosome 1q23
Puri V, McQuillin A, Datta S, Choudhury K, Pimm J, Thirumalai S, Krasucki R, Lawrence J, Quested D, Bass N, Crombie C, Fraser G, Walker N, Moorey H, Ray MK, Sule A, Curtis D, St Clair D, Gurling H
3 Eur J Hum Genet
PMID 18414510
Secretion stimulates intramembrane proteolysis of a secretory granule membrane enzyme
Rajagopal C, Stone KL, Mains RE, Eipper BA
J Biol Chem 2010 Nov 5;285(45):34632-42
PMID 20817724
Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer
Zhang D, Tari AM, Akar U, Arun BK, LaFortune TA, Nieves-Alicea R, Hortobagyi GN, Ueno NT
Mol Cancer Ther 2010 Nov;9(11):3090-9
PMID 21045138


This paper should be referenced as such :
Vanessa Cristina Arfelli, Leticia Frhlich Archangelo
UHMK1 (U2AF homology motif kinase 1)
Atlas Genet Cytogenet Oncol Haematol. 2018;22(8):328-335.
Free journal version : [ pdf ]   [ DOI ]

External links


HGNC (Hugo)UHMK1   19683
Entrez_Gene (NCBI)UHMK1    U2AF homology motif kinase 1
AliasesKIS; KIST; P-CIP2
GeneCards (Weizmann)UHMK1
Ensembl hg19 (Hinxton)ENSG00000152332 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000152332 [Gene_View]  ENSG00000152332 [Sequence]  chr1:162497818-162529631 [Contig_View]  UHMK1 [Vega]
ICGC DataPortalENSG00000152332
TCGA cBioPortalUHMK1
Genatlas (Paris)UHMK1
SOURCE (Princeton)UHMK1
Genetics Home Reference (NIH)UHMK1
Genomic and cartography
GoldenPath hg38 (UCSC)UHMK1  -     chr1:162497818-162529631 +  1q23.3   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)UHMK1  -     1q23.3   [Description]    (hg19-Feb_2009)
GoldenPathUHMK1 - 1q23.3 [CytoView hg19]  UHMK1 - 1q23.3 [CytoView hg38]
Genome Data Viewer NCBIUHMK1 [Mapview hg19]  
Gene and transcription
Genbank (Entrez)AJ536197 AK026668 AK058195 AK292369 AL137257
RefSeq transcript (Entrez)NM_001184763 NM_144624 NM_175866
Consensus coding sequences : CCDS (NCBI)UHMK1
Gene ExpressionUHMK1 [ NCBI-GEO ]   UHMK1 [ EBI - ARRAY_EXPRESS ]   UHMK1 [ SEEK ]   UHMK1 [ MEM ]
Gene Expression Viewer (FireBrowse)UHMK1 [ Firebrowse - Broad ]
GenevisibleExpression of UHMK1 in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)127933
GTEX Portal (Tissue expression)UHMK1
Human Protein AtlasENSG00000152332-UHMK1 [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ8TAS1   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtQ8TAS1  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProQ8TAS1
Catalytic activity : Enzyme2.7.11.1 [ Enzyme-Expasy ] [ IntEnz-EBI ] [ BRENDA ] [ KEGG ]   [ MEROPS ]
Domaine pattern : Prosite (Expaxy)PROTEIN_KINASE_DOM (PS50011)    RRM (PS50102)   
Domains : Interpro (EBI)Kinase-like_dom_sf    Nucleotide-bd_a/b_plait_sf    Prot_kinase_dom    RBD_domain_sf    RRM_dom    UHMK1    UHMK1_RRM   
Domain families : Pfam (Sanger)Pkinase (PF00069)    RRM_1 (PF00076)   
Domain families : Pfam (NCBI)pfam00069    pfam00076   
Domain families : Smart (EMBL)RRM (SM00360)  S_TKc (SM00220)  
Conserved Domain (NCBI)UHMK1
AlphaFold pdb e-kbQ8TAS1   
Human Protein Atlas [tissue]ENSG00000152332-UHMK1 [tissue]
Protein Interaction databases
IntAct (EBI)Q8TAS1
Ontologies - Pathways
Ontology : AmiGORNA binding  protein serine/threonine kinase activity  protein serine/threonine kinase activity  protein binding  ATP binding  nucleus  nucleus  nucleoplasm  nucleoplasm  Golgi apparatus  transferase activity  peptidyl-serine phosphorylation  peptidyl-serine phosphorylation  peptidyl-serine phosphorylation  axon  midbody  neuron projection development  dendrite cytoplasm  ribonucleoprotein complex binding  ribonucleoprotein complex binding  positive regulation of translational initiation  positive regulation of translational initiation  protein autophosphorylation  regulation of protein export from nucleus  regulation of protein export from nucleus  regulation of cell cycle  regulation of cell cycle  neuronal ribonucleoprotein granule  neuronal ribonucleoprotein granule  protein serine kinase activity  protein threonine kinase activity  
Ontology : EGO-EBIRNA binding  protein serine/threonine kinase activity  protein serine/threonine kinase activity  protein binding  ATP binding  nucleus  nucleus  nucleoplasm  nucleoplasm  Golgi apparatus  transferase activity  peptidyl-serine phosphorylation  peptidyl-serine phosphorylation  peptidyl-serine phosphorylation  axon  midbody  neuron projection development  dendrite cytoplasm  ribonucleoprotein complex binding  ribonucleoprotein complex binding  positive regulation of translational initiation  positive regulation of translational initiation  protein autophosphorylation  regulation of protein export from nucleus  regulation of protein export from nucleus  regulation of cell cycle  regulation of cell cycle  neuronal ribonucleoprotein granule  neuronal ribonucleoprotein granule  protein serine kinase activity  protein threonine kinase activity  
Pathways : BIOCARTAStathmin and breast cancer resistance to antimicrotubule agents [Genes]   
REACTOMEQ8TAS1 [protein]
REACTOME PathwaysR-HSA-9634638 [pathway]   
NDEx NetworkUHMK1
Atlas of Cancer Signalling NetworkUHMK1
Wikipedia pathwaysUHMK1
Orthology - Evolution
GeneTree (enSembl)ENSG00000152332
Phylogenetic Trees/Animal Genes : TreeFamUHMK1
Homologs : HomoloGeneUHMK1
Homology/Alignments : Family Browser (UCSC)UHMK1
Gene fusions - Rearrangements
Fusion : MitelmanUHMK1::DDR2 [1q23.3/1q23.3]  
Fusion : MitelmanUHMK1::PPOX [1q23.3/1q23.3]  
Fusion : QuiverUHMK1
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerUHMK1 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)UHMK1
Exome Variant ServerUHMK1
GNOMAD BrowserENSG00000152332
Varsome BrowserUHMK1
ACMGUHMK1 variants
Genomic Variants (DGV)UHMK1 [DGVbeta]
DECIPHERUHMK1 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisUHMK1 
ICGC Data PortalUHMK1 
TCGA Data PortalUHMK1 
Broad Tumor PortalUHMK1
OASIS PortalUHMK1 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICUHMK1  [overview]  [genome browser]  [tissue]  [distribution]  
Somatic Mutations in Cancer : COSMIC3DUHMK1
Mutations and Diseases : HGMDUHMK1
LOVD (Leiden Open Variation Database)[gene] [transcripts] [variants]
DgiDB (Drug Gene Interaction Database)UHMK1
DoCM (Curated mutations)UHMK1
CIViC (Clinical Interpretations of Variants in Cancer)UHMK1
NCG (London)UHMK1
Impact of mutations[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Genetic Testing Registry UHMK1
NextProtQ8TAS1 [Medical]
Target ValidationUHMK1
Huge Navigator UHMK1 [HugePedia]
Clinical trials, drugs, therapy
Protein Interactions : CTDUHMK1
Pharm GKB GenePA134974001
Clinical trialUHMK1
DataMed IndexUHMK1
PubMed29 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Oct 8 21:30:25 CEST 2021

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us